Management of adverse events in patients with metastatic renal cell carcinoma treated with sunitinib and clinical outcomes

Maki Arakawa-Todo, Takahiko Yoshizawa, Kenji Zennami, Genya Nishikawa, Yoshiharu Kato, Ikuo Kobayashi, Keishi Kajikawa, Yoshiaki Yamada, Katsuhiko Matsuura, Ikuto Tsukiyama, Hiroko Saito, Takaaki Hasegawa, Kogenta Nakamura, Makoto Sumitomo

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)

Abstract

Patients with progressive renal cell carcinoma who undergo sunitinib treatment, experience many adverse events (AEs), including thrombopenia and hypertension. Dose reduction or treatment discontinuation due to AEs makes it difficult to control the clinical condition. Therefore, patients' understanding regarding the basics of blood pressure (BP) measurement and how to deal with each AE are particularly important. Here we report whether or not pharmacist instructions help in order to increase patients' awareness of early AE management results in an improvement of treatment outcomes. The present study included 15 patients who were administered sunitinib. From the start of sunitinib treatment, pharmacists continuously provided drug administration guidance to the patients and confirmed their awareness and knowledge regarding AEs, symptom management, and drug adherence. The relative dose intensity (RDI) of 15 patients from week 1 to 24 after sunitinib treatment was calculated. Pharmaceutical interventions significantly improved patients' understanding of BP measurements and reference values, etc. Although the RDI was 67.3%-78.7%, there were no cases of discontinuation of administration or reduction of the dose caused by e.g. hypertension, hand and foot syndrome (HFS) and stomatitis. Pharmaceutical interventions improved patients' awareness of the management of AEs and adherence to sunitinib therapy. As a result, a high RDI was maintained, which may lead to prolonged survival. Therefore, our results suggest that early AE management provided by pharmacists is particularly important to assure the safety and efficacy of sunitinib therapy.

Original languageEnglish
Pages (from-to)5043-5050
Number of pages8
JournalAnticancer research
Volume33
Issue number11
Publication statusPublished - 01-11-2013
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Management of adverse events in patients with metastatic renal cell carcinoma treated with sunitinib and clinical outcomes'. Together they form a unique fingerprint.

Cite this